Future research is needed however, as this novel drug treatment has not been replicated in clinical studies on humans, who may present with complicating factors such as comorbidities, advanced age, or environmental variables that may play a role in disease outcomes. The combination treatment was effective in preventing the development of invasive disease. pneumoniae and enhanced the bacteria's susceptibility to antibiotics and reduced bacterial burden in the lungs of mice with pneumonia. The researchers found that using Fomepizole blocked normal energy production by S. They quantified the bacterial burden in the organs of infected mice, comparing the experimental group with the control group. pneumoniae and tested the effect of fomepizole in a combinatorial treatment with antibiotics. Researchers inoculated mice with a multidrug-resistant S. Fomepizole is an FDA-approved drug normally used as an antidote for the ingestion of toxic alcohols (such as methanol or ethylene glycol), and works by inhibiting the enzyme alcohol dehydrogenase. pneumoniae, the researchers conducted a series of experiments with mice. In order to test the effects of novel treatments for antibiotic-resistant S. Currently, there are very limited treatment options for combating multidrug-resistant S. While vaccines to protect against the bacteria are available, these vaccines are not effective against all strains, with some versions being especially problematic as they are multidrug-resistant. Streptococcus pneumoniae is the leading cause of community-acquired pneumonia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |